Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

For some, the issue with GLP-1 drugs like Ozempic and Mounjaro isn't getting access to these game-changing medications, but ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

A new class of weight-loss drugs touted as a revolutionary breakthrough in obesity management have received global attention, ...

The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

We recently published a list of 12 Most Profitable Pharmaceutical Stocks Right Now. In this article, we are going to take a ...

Most people taking drugs like Ozempic and Wegovy have shed significant pounds. But obesity experts say that roughly 20% of ...